Tocilizumab fails to improve condition of severe Covid-19 patients

The result of the COVACTA study dashes the hopes of experts who were
looking to use the rheumatoid arthritis drug as treatment option for
Covid-19 patients. Tocilizumab is sold by Roche under the brand
Acetmra.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/tocilizumab-fails-to-improve-condition-of-severe-covid-19-patients/articleshow/77245090.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment